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N
ucleic acid-based therapy holds the
potential for a new era in the treatment
of life-threatening disease. Advances in
the use of antisense oligodeoxynucleotides
(ODNs) as inhibitor of aberrant gene expres-
sion in neoplastic cells have been reviewed in a
recent issue of this Journal;1,2 since new reports
are continuously appearing, the present state of
the art needs to be defined again. 
The optimism generated by promising results
obtained in different cellular systems is tem-
pered by the difficulties in developing clinical
trials, mainly because of the lack of sufficient
knowledge regarding the mechanisms associat-
ed with the inhibition of gene expression in
vitro and in vivo. For example, the duration of
ODN survival inside the cells, the most appro-
priate ODN length to produce specific inhibi-
tion of gene expression, ODN plasma levels, tis-
sue distribution and concentration in animals
are some of the aspects that need to be investi-
gated and clarified before a drug can be devel-
oped for clinical use.
Antisense oligodeoxynucleotides for chronic
myelogenous leukemia 
Chronic myelogenous leukemia (CML) repre-
sents a suitable candidate for antisense therapy.
The reciprocal translocation between chromo-
somes 9 and 22 t(9;22)(q34;q11) generates the
Philadelphia chromosome and the fusion gene
BCR-ABL, which is transcribed into a mRNA
and translated into a p210 BCR-ABL protein.3,4
It has been clearly demonstrated that this gene
and its product play a role in the pathogenesis
of CML5 and that the greater intrinsic protein
tyrosine kinase activity of p210 is presumably
responsible for its transforming potential.6 The
bcr-abl hybrid transcripts generated by the
t(9;22) translocation are ideally suited for anti-
sense-based therapy; furthermore, CML
remains a fatal disease which might benefit
from experimental approaches.
Two genes, c-myb and bcr-abl, have been tar-
geted with antisense ODNs to inhibit their
functions.
c-myb is preferentially expressed in hemato-
poietic cells. Its down-regulation is associated
with increased cell maturation and is required
for normal and leukemic hematopoiesis in vitro
and in vivo. The apparent limitation to using
antisense ODNs that may affect the prolifera-
tion of both normal and leukemic progenitors
was circumvented by the demonstration that
normal and leukemic hematopoietic cells show
differential sensitivity to the effect of c-myb
antisense ODNs: normal hematopoietic cells
survived at doses inhibiting leukemic cell
growth.7 More recently, a series of CML patients
in acute and in chronic phase were studied in
vitro to determine the frequency of elimination
of bcr-abl expressing cells following treatment
with c-myb antisense ODNs. In 8 of the 11 cases
treated there was a marked reduction in the
colony-forming ability of CML cells. Inhibition
was antisense sequence specific, dose dependent
and ranged between 58 and 93% of control
growth. Furthermore, evaluation of residual
colonies for bcr-abl m-RNA expression using
reverse transciption-polymerase chain reaction
(r-PCR) showed that bcr-abl expression was
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either greatly decreased or undetectable.8
The other well-characterized target for anti-
sense inhibition of CML cells is the breakpoint
junction on bcr-abl m-RNA transcripts. Two
bcr-abl m-RNAs can be transcribed from the
fusion gene; in fact, c-abl exon 2 is coupled
either with exon 2 (B2A2) or with exon 3
(B3A2) of bcr.9 Antisense ODNs of different
length (16-26 bases), designed against the
breakpoint of these two mRNAs, appear capable
of inhibiting Philadelphia-positive cells and
sparing normal hematopoietic progenitors.
The first demonstration that CML cells might
be susceptible to p210 bcr-abl down-regulation
was the finding that leukemic cell growth from
patients with CML in blastic phase was sup-
pressed by 18-mer antisense ODNs, whereas
colony formation from normal progenitors was
unaffected. Interestingly, when equal amounts
of normal marrow progenitors and blast cells
were mixed and exposed to ODNs, the majority
of residual colonies were normal.10 Interest in
the potential application of bcr-abl antisense
ODNs in clinical settings, at least as in vitro
purging agents, stimulated other studies aimed
at better defining conditions that may influence
in vitro elimination of leukemic cells by bcr-abl
antisense ODNs,11 or at combining agents with
different mechanisms of action to develop more
effective purging procedures.12 The combina-
tion, in fact, of low-dose mafosfamide and bcr-
abl antisense ODNs caused complete disap-
pearance of bcr-abl transcripts in the experi-
mental conditions used, suggesting very effi-
cient elimination of leukemic cells from bone
marrow.
A more clinically relevant use of bcr-abl anti-
sense ODNs would be the treatment of Phi-
ladelphia-positive cells from patients in chron-
ic rather than in blastic phase, provided the
antileukemic effect of bcr-abl antisense ODNs
is still marked on cells from patients in an ear-
lier phase of the disease. In the past few years
conflicting results have been generated on the
actual elimination of Ph-positive cells from
patients with CML in chronic phase.1 3 - 1 5
Recently, Kirkland et al. reported experiments
on 15 patients in chronic phase tested with 18-
mer and 26-mer antisense phosphorothioate
ODNs. Modest non-specific inhibition was
observed, highlighted by a similar effect being
shown by the corresponding junctional m-
RNA antisense and by the alternative junction-
al antisense ODNs, suggesting that clinical tri-
als of bone marrow purging with bcr-abl anti-
sense ODNs might be premature.15 In this
study, however, incubation of the cells with
ODNs lasted only 24-hours, which might be
too short to produce a marked specific
antileukemic effect. Similarly, the same authors
examined the effects of different antisense
oligomers on the proliferation of several cell
lines. In general, phosphodiester ODNs were
inactive, presumably due to degradation by
nucleases present in fetal calf serum; however,
both B2A2 and B3A2 phosphorothioate anti-
sense ODNs significantly inhibited prolifera-
tion of 3 out of 8 cell lines tested. The effect
was independent of the type of breakpoint
expressed by each cell line, suggesting that the
inhibition was sequence dependent but not
sequence specific.16 In this study, the specific
down-regulation or degradation of bcr-abl
mRNA or protein after exposure to antisense
ODNs was not evaluated, and further studies
are necessary to delineate the precise mecha-
nisms by which CML cells are inhibited by
antisense ODNs. 
We analyzed a series of patients with CML in
chronic phase using both 16-mer and 26-mer
antisense phosphorothioate ODNs (Lynx
Therapeutics Inc, Hayward, USA); we evaluated
both the duration of incubation and the sensi-
tivity to ODNs of a more immature compart-
ment of CML cells (CD34+ cells) (manuscript
in preparation). From our results it seems that
120 hours of incubation and the use of CD34+
concentrated cells are prerequisites for a better
antileukemic effect of antisense ODNs, and that
patients with CML could be selected for auto-
grafting with antisense-purged bone marrow
cells on the basis of in vitro response.
New aspects in oligodeoxynucleotides research
A number of studies investigated the mecha-
nism of action of ODNs with the aim of
increasing antileukemic effect. In a recent work,
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the use of fluorescein-labeled phosphorothioate
ODNs allowed evaluation of ODN uptake by
the BV173 cell line. ODN uptake was depen-
dent on the extracellular concentration and was
constant over the first 18 hours of incubation.
A decrease in bcr-abl m-RNA was seen only
after 3 days of treatment and a large number of
apoptotic cells were observed in the antisense-
treated group.17 These data seem to confirm our
observation that prolonged incubation is need-
ed to produce effective antisense activity and
that perhaps repeated administrations of anti-
sense might be useful in increasing the elimina-
tion of rearranged cells.
As a step toward enhancing target selectivity
and thereby the differential effects of these
reagents on leukemic cells, a DNA delivery sys-
tem based on receptor-mediated endocytosis
was recently adapted to introduce ODNs com-
plexed with a transferrin polylysine conjugate
into HL-60 cells.18,19 Transferrin receptors are
abundantly expressed on the surface of tumor
cells and, in principle, provide a simple mecha-
nism for the preferential delivery of ODNs in
tumor cells. The efficiency of this approach
might have been overestimated by the use of a
leukemic cell line, in which transferrin recep-
tors are probably much more homogeneously
distributed than they are on primary tumor
cells; however, the combined use of free and
complexed ODNs might be considered since
they are likely to utilize different pathways to
enter the target cells. 
Phosphorothioate ODNs are the most com-
monly used derivative of unmodified, natural
ODNs. They hybridize efficiently to comple-
mentary RNA sequences, thereby blocking
transcription and translation, and are able to
recruit Rnase H, which cleaves the RNA com-
ponent of the RNA/DNA duplex. On the other
hand, phosphorothioate ODNs exhibit
sequence-independent mechanisms of activity
in vitro,2 0 , 2 1 which may (or may not) have
adverse effects in vivo. Accordingly, the future
development of second-generation classes of
modified ODN analogues seems to be likely in
the evolution of successful clinical applications
in therapies based on the down-regulation of
oncogene expression.
Use of antisense oligodeoxynucleotides for ex
vivo purging of chronic myelogenous leukemia
bone marrow
Autologous bone marrow transplantation is
increasingly being used for the treatment of
CML, with encouraging results in terms of
antileukemic effect and prolongation of sur-
vival.22 Autograft is usually performed with
unmanipulated marrow or peripheral blood,
since the general view of a stem cell-involving
disease has hampered the possibility of purging
leukemic cells and reinfusing residual normal
stem cells. Evidence, however, was recently
reported that a normal population of progenitor
cells may survive in the majority of Ph-positive
CML,23,24 and several purging strategies have
already been developed both experimentally and
clinically.25,26 The demonstration that c-myb or
bcr-abl antisense ODNs may inhibit colony for-
mation of CML cells (consequently sparing the
normal stem cell counterpart) has stimulated
the possible application of antisense ODNs to
bone marrow purging.
We started a phase-1 trial on autografting with
bcr-abl antisense, ODN-purged marrow in
patients with CML in advanced phase.27 The
major aim of this study was to evaluate the anti-
leukemic effect of antisense in vitro and the
effect of ODN purging on bone marrow engraft-
ment and hematologic reconstitution. For this
pilot study we decided not to exceed 24-hour
incubation with antisense ODNs in order to
avoid the risk of engraftment failure related to
in vitro manipulations.28 The concentration of
antisense ODNs (150 ug/mL) was chosen on the
basis of dose-escalating experiments which
demonstrated a lack of toxicity on normal mar-
row progenitors up to 160 ug/mL of antisense.
The results, although preliminary, clearly
demonstrated the possibility of purging CML
patients in vitro with antisense ODNs and
engrafting the treated marrow after a time inter-
val similar to that observed in unpurged
patients in historical controls.29
Autografting with CD34+ marrow cells treated
in vitro with c-myb antisense ODNs is currently
being carried out at the University of Penn-
sylvania in Philadelphia, USA, under the direc-
tion of Dr Alan Gewirtz. Preliminary results in
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10 CML patients who underwent this procedure
confirm the lack of toxicity of the ex vivo treat-
ment, as reflected by the re-establishment of
hematopoiesis. In some patients, Philadelphia-
positive cells were markedly reduced, raising the
possibility of a long-term therapeutic effect of
the procedure.30
Conclusions
The generation of antisense ODNs specific
for gene rearrangements in human cancer has
brought renewed optimism to the possibility of
specifically treating these genetic abnormality-
related malignancies. The ultimate goal of these
programs is to develop efficient antisense thera-
pies for the in vivo treatment of human leuke-
mias, provided that problems of toxicity, uptake
and specificity can be solved. There are, howev-
er, several animal studies which may encourage
researchers to proceed toward future therapy
with antisense ODNs. Recently, the possibility
of eradicating leukemia in SCID mice treated
systemically with bcr-abl phosphorothioate
antisense ODNs was explored.31 Leukemic mice
were given antisense intravenously for 9 consec-
utive days and evaluated both for the presence
of residual leukemic cells in several tissues and
for the effect on survival. Bcr-abl transcripts
were not detected in six different tissues of anti-
sense-treated mice and all these animals were
alive 16 weeks after leukemia cell injection,
whereas untreated and sense-treated mice were
dead 10-13 weeks after injection.
Before systemic administration of antisense
ODNs in patients with CML can begin, appro-
priate studies of pharmacokinetics, organ distri-
bution and function, some of which have
already been conducted in animals, must be
performed.32,33 From the experiments already
conducted it would seem that few adverse effects
are associated with plasma ODN concentrations
that may be therapeutic; furthermore, as far as
the cost and production of ODNs are con-
cerned, clinical trials would seem to be feasible.
However, the ODN plasma half-life found
would indicate that daily administration is
preferible, although very little is known about
the toxicity associated with chronic ODN infu-
sion. Certainly, before chronic therapy can be
considered, issues related to metabolism and
reutilization of metabolites must be addressed.
As discussed above, the association of ODNs
with antiproliferative agents with a different
mechanism of action seems to increase the
antileukemic activity of bcr-abl ODNs in vitro.12
The possible in vivo association of antisense
ODNs with agents used regularly for the treat-
ment of CML could be an interesting approach
if the appropriate in vitro and animal studies are
conducted carefully.
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